← All Casi Pharmaceuticals, INC filings

Casi Pharmaceuticals, INC 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

CASI
Casi Pharmaceuticals, INC
20-F: CASI Pharmaceuticals Divests China Operations, Focuses on CID-103
CASI Pharmaceuticals announced a strategic shift, divesting its China-based subsidiaries and pipeline assets to focus on the global development of its CID-103 drug candidate.
CASI
Casi Pharmaceuticals, INC
20-F: CASI Pharmaceuticals Reports FY24 Results Amidst Strategic Review and Market Challenges
CASI Pharmaceuticals faces operating losses and a non-binding acquisition proposal while navigating market competition and regulatory hurdles in China.
CASI
Casi Pharmaceuticals, INC
20-F: CASI Pharmaceuticals Bolsters Intellectual Property with Cleave Therapeutics Acquisition, Outlines Financials in 20-F Filing
CASI Pharmaceuticals acquires global rights to CB-5339 from Cleave Therapeutics and details financial performance, risks, and strategies in its annual 20-F filing.